However, numerous clinical trials utilizing CTLA-4 or PD-1/PD-L1 inhibitors in patients with metastatic castration-resistant PCa (mCRPC) have been disappointing, with limited survival benefits when administered as monotherapy in unselected patients12,13,45,50,51. This evidence concerns the gene CTLA4 and posterior cortical atrophy.